Clinical Trial Insights in Retinal Vascular Diseases

In this episode, “Clinical Trial Insights in Retinal Vascular Diseases,” the panelists explore key clinical trial data evaluating next-generation anti-VEGF therapies for neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). The discussion highlights how pivotal Phase III studies are shaping treatment decisions in clinical practice, particularly regarding durability, dosing intervals, safety, and long-term disease management.

The expert faculty review data from the PULSAR, PHOTON, and QUASAR studies evaluating aflibercept 8 mg across retinal vascular diseases. The panel discusses how these trials demonstrated extended dosing intervals, with many patients achieving treatment intervals of up to 16 weeks and beyond while maintaining visual acuity outcomes comparable to earlier-generation therapies. The discussion also highlights the evolving long-term extension data supporting treatment durability and reviews the safety profile of aflibercept 8 mg, including the absence of new safety signals or significant intraocular pressure concerns despite the higher injection volume.

In addition, the panel reviews key faricimab clinical trials, including TENAYA, LUCERNE, YOSEMITE, RHINE, BALATON, and COMINO, and discusses how dual-pathway inhibition may contribute to improved fluid control and durability across AMD, DME, and RVO. The expert faculty also examine how these trial findings influence treatment selection and helping clinicians better individualize therapy for patients with retinal vascular diseases. Throughout the discussion, the panel emphasizes the growing role of durable anti-VEGF therapies in reducing treatment burden while maintaining efficacy and safety.

The next episode in this series, “Safety and Durability in Therapies for Retinal Vascular Diseases,” features the panelists discussing how retina specialists evaluate the safety profile of next-generation anti-VEGF therapies while extending treatment intervals and reducing injection burden. The expert faculty also examine how increased durability may be achieved without introducing new safety concerns or additional monitoring requirements in clinical practice.